Pilot study of a new retinoid, Ro 12-7554, in psoriasis and in some congenital disorders of keratinization.
Ro12-7554, a chlorinated derivative of etretinate, was evaluated in an open study. 16 patients, 13 suffering from severe psoriasis and 3 from congenital disorders of keratinization previously treated with etretinate, received Ro 12-7554 at a mean daily dosage of 12.3 mg/day. Ro 12-7554 was very similar to etretinate in terms of clinical efficacy and overall safety.
D000328:Adult; D003873:Dermatitis, Exfoliative / Q000188:drug therapy*; D004341:Drug Evaluation; D005050:Etretinate / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007642:Keratosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D012872:Skin Diseases, Vesiculobullous / Q000188:drug therapy*; D014212:Tretinoin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D014212:Tretinoin; D005050:Etretinate; C038961:Ro 12-7554